Skip to main content

Table 1 Characteristics of the studies included in the analysis

From: The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials

First author (publication year)

Study design

Histology type

FIGO stage

Debulking Surgery

Group

Number of patients

Median age (y)

Definition of SL and USL

Harter (2019) [18]

RCT

Epithelial ovarian cancer

IIB–IV

R0

SL

323

60

systematic pelvic and aortic lymphadenectomy

USL

324

60

no lymphadenectomy

Maggioni (2006) [23]

RCT

Epithelial ovarian cancer

I–II

R1

SL

138

51

systematic pelvic (≥20) and aortic (≥15) lymphadenectomy

USL

130

52

random removal of pelvic and para-aortic LNs (sampling)

Panici (2005) [22]

RCT

Epithelial ovarian cancer

IIIB–IV

R1

SL

189

53

systematic pelvic (≥25) and aortic (≥15) lymphadenectomy

USL

195

56

bulky nodes only

Dell’ Anna (2012) [24]

RCT

Epithelial ovarian cancer

I–IV

R1

SL

158

50

systematic pelvic (≥25) and aortic (≥15) lymphadenectomy

USL

150

52

bulky nodes only

  1. RCT randomized controlled trial, FIGO International Federation of Gynecology and Obstetrics, R0 no residual tumor, R1 residual tumor < 1 cm, SL systematic lymphadenectomy, USL unsystematic lymphadenectomy